FDA Determines Regulatory Review Period for NAVITOR TRANSCATHETER AORTIC VALVE IMPLANT

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for patent extension of the NAVITOR TRANSCATHETER AORTIC VALVE IMPLANT, following submissions to the US Patent and Trademark Office (USPTO).